☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
All Posts by Date
Reviva Reports First Patient Dosing in P-III Study of Brilaroxazine for the Treatment of Schizophrenia
February 1, 2022
Coherus BioSciences Reports the Pooled Analysis of Udenyca (biosimilar, pegfilgrastim) Demonstrated Similar Immunogenicity to Neul...
February 1, 2022
MaxCyte Signs a Strategic Platform License with Intima Bioscience to Boost Tumor Infiltrating Lymphocytes Programs for Solid Tumor...
February 1, 2022
Takeda’s Vonvendi Receives the US FDA’s Approval for the Treatment of Severe Type 3 Von Willebrand Disease
February 1, 2022
Madrigal Reports Results of Resmetirom in P-III (MAESTRO-NAFLD-1) Study for the Treatment of Non-Alcoholic Steatohepatitis
February 1, 2022
Kite’s Yescarta (axicabtagene ciloleucel) Receives the US FDA’s Approval for New Label Update in all Approved Indications
February 1, 2022
Load more...
Back to Home
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions